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ABSTRACT 
Diabetic macular edema (DME) is a significant cause of blindness in the working population and is currently challenging 
to treat. Current interventions include focal laser or intravitreal injections. This article outlines a new treatment protocol 
based on the theory that peripheral ischemia is the precursor to angiogenesis, which will ultimately gather its 
momentum at the fovea. Extreme peripheral light laser panretinal photocoagulation (PRP) back to the equator reduces 
excessive production of the vascular endothelial growth factor (VEGF) in the eye. This decreases VEGF-induced DME and 
provides long-term protection against the development of neovascularization. Initial exacerbation of DME often 
accompanies PRP. Therefore, injections of anti-VEGF agents (with or without dexamethasone implants) initially can 
forestall worsening of DME and prevent loss of vision. However, on the other hand, applying peripheral PRP and 
intraocular injections can induce posterior vitreous detachment (PVD). This could help release vitreomacular adhesions 
(VMA) and vitreomacular traction (VMT), thereby decreasing DME severity and improving the response to intravitreal 
injections. In the current approach, peripheral retinal photocoagulation should stop the drive for VEGF release; 
moreover, laser ablation should produce secondary, accidental, and beneficial PVD. This approach precludes focal laser 
therapy and paves the path for prolonged intervals between anti-VEGF therapy. 
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INTRODUCTION 
Diabetic macular edema (DME) is a multifactorial, 
complex and major cause of blindness worldwide. The 
disease involves breakdown of the blood-retinal barriers, 
oxidative stress, and increased growth factors [including 
vascular endothelial growth factor (VEGF)] (1). Current 
interventions include control of systemic comorbidities 
(e.g., hyperglycemia, dyslipidemia, and systemic 
hypertension). Ophthalmic treatments include 
monotherapy or a combination of focal macular laser 
photocoagulation (argon vs. subthreshold micropulse 
diode) and intravitreal pharmacotherapy (triamcinolone, 
dexamethasone or fluocinolone implants, ranibizumab, 
bevacizumab, aflibercept). Several studies (2, 3) have 
shown that anti-VEGF therapy is somewhat effective in 
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controlling DME, even in cases where focal macular laser 
treatment has failed. Following FDA approval, 
ranibizumab and aflibercept have become the first-
choice therapy for DME (4). The introduction of 
ranibizumab for the management of DME has shifted the 
approach to this entity dramatically. Focal laser 
photocoagulation is still a preferred treatment for DME 
not involving the center of the macula (5). The Early 
Treatment Diabetic Retinopathy Study (ETDRS) showed 
that focal photocoagulation in eyes with DME reduced 
the risk of moderate visual loss, while scatter 
photocoagulation did not (6, 7). The high intensity of the 
laser burn used in the ETDRS protocol was associated 
with enlargement of laser scars, acute induction of 
choroidal neovascularization, long-term subretinal 
fibrosis, and frequent visual field loss (8). The Diabetic 
Retinopathy Clinical Research Network (8) and other 
researchers (9, 10) recently recommended mild grid laser 
photocoagulation. 
Intravitreal anti-VEGF drugs have continuously shown 
good clinical effectiveness without significant 
undesirable side effects and achieved vision gains of ten 
or more letters on ETDRS charts in 50% of treated eyes 
(4). In addition, intravitreal anti-VEGF drugs can improve 
diabetic retinopathy but require repeated injections (1). 
Intravitreal corticosteroids are used when anti-VEGF 
agents fail, although there were complications such as 
ocular hypertension and formation of cataract. Despite 
the current availability of a number of treatments for 
DME, only a proportion of patients recover good vision (≥ 
6/12 or 20/40) (4), and thus the search for newer 
therapies is in order. 
This article outlines a new treatment protocol based on 
the theory that peripheral ischemia is the primer for 
angiogenesis with the responder site being the fovea. 
 
THE HYPOTHESIS/THEORY  
Technique 
1. Maximal pupil dilation (cyclopentolate 1%, mydriacyl 
1%, phenylephrine 10%) 
2. Minimal energy to reduce blanching panretinal 
photocoagulation laser burns (argon green, 0.1 second; 
200 microns spot size; 1 place apart.) 
3. Use of high-resolution wide-field laser lens (17) (Volk 
Optical, Mentor, Ohio, USA) 
4. Treat regions from the outer periphery to equator with 
special attention to any ischemic areas apparent on 
ultrawide field intravenous fluorescein angiography 
(IVFA) (a minimum of 1000 and a maximum of around 
2000 shots) 
5. No need for retrobulbar anesthesia. Prepare patients 
with a low pain threshold by administering nonsteroidal 
anti-inflammatory medications an hour before the 
procedure 
6. The laser is in a continuous mode with 0.1 sec pause 
and session lasting approximately five minutes. 
Peripheral ischemia is an important finding in eyes with 
DME (11-14), which is highlighted even more by new 
technological advances in wide-angle fluorescein 
angiography. The modern approach suggests that 
treating this peripheral ischemia is a pivotal issue in DME 
therapy. Namely, peripheral ischemia leads to up-
regulation of VEGF (14-16), and ablation of the periphery 
would result in down-regulation of VEGF. The use of 
recently available wide-angle lenses (17-19) in the 
application of the laser beam to extreme outer periphery 
has given fresh impetus to this new therapy. 
Furthermore, peripheral laser photocoagulation 
enhances formation of posterior vitreous detachment 
(PVD) (20), which enhances DME resolution. To prevent 
the immediate transient worsening of DME after laser, 
intravitreal anti-VEGF (with or without corticosteroid 
implant) is initially administered along with laser therapy. 
Multiple intravitreal injections like anti-VEGF agents 
increases the likelihood for PVD formation as well (21). 
Photocoagulation leads to increased oxygen supply to 
the remaining retina, especially the area of macula. This 
results in retinal vasoconstriction and a decrease in DME, 
avoiding the need for both focal therapies of the 
posterior pole and repeated anti-VEGF injections. In 
addition, it protects against the occurrence of 
neovascular glaucoma and vitreous hemorrhage. 
EVALUATION OF THE HYPOTHESIS/IDEA 
Half a decade ago, Wise and Wangvivat (22) thought that 
the macula mounts an exaggerated response to 
peripheral retinal disorders, such as diabetic retinopathy. 
Recently, Otani et al. (23) showed again that peripheral 
retinal vascular leakage could lead to serous retinal 
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detachment in the macula. More recently, peripheral 
vascular leakage was documented in diabetic retinopathy 
by Oliver (12). The macula appears to act as a sink where 
pathologic processes occurring outside can secondarily 
evolve by the gravitational leakage, VEGF up-regulation, 
or vitreous biochemical changes leading to vitreomacular 
interface changes. 
The ability to identify and hence treat ischemia of the 
peripheral retina may control DME since the 
nonperfused retina acts as a major source of VEGF 
production. The link between DME and peripheral retinal 
nonperfusion was initially described by Shimizu et al. in 
1981 and in later years (24-26) using a 60o wide-angle 
IVFA camera. Additional findings of peripheral 
nonperfusion have been strongly correlated with DME 
(27). Recently,  midperipheral nonperfusion was 
detected in 84% of eyes with DME and nonproliferative 
retinopathy (28). This was confirmed by other studies 
using ultrawide field imaging (15): 
Peripheral vascular nonperfusion was detected in around 
two-thirds of eyes with severe non-proliferative diabetic 
retinopathy (non-PDR) and proliferative diabetic 
retinopathy (PDR) using ultrawide field IVFA. 
Angiographic characteristics of 264 eyes of 143 patients 
were evaluated. Among untreated eyes with 
nonproliferative retinopathy and DME, there was a trend 
for association of DME and peripheral nonperfusion (p = 
0.065) (12, 13). According to Wessel et al. (29), eyes with 
retinal ischemia have a 3.75 times greater chance of 
developing DME. 
Visualization of the peripheral retina is important for 
detailed angiographic retinal examination as well as for 
delivery of peripheral PRP in proliferative retinal 
diseases. Retinal ischemia is best visualized with IVFA. 
Traditional IVFA employs retinal photography that 
visualizes 30° of the retina at one time. The ETDRS 
developed the protocol of seven-standard fields (7SF) 
photographed areas and these are combined give close 
to 75° of visualization. With the advent of ultrawide-field 
fluorescein angiography (Optos 200Tx, Dunfermline, 
Scotland), 200° of retina is seen in a single photograph. 
Various contact and non-contact lens systems are 
available to allow panoramic visualization and therapy of 
the retina (19). The wide-field contact lens system 
(SuperQuad 160) uses even a wider aperture to expand 
the field of view, and similarly for the miniaturized HR 
wide-field contact lens (17, 18). 
This newly described approach avoids focal therapy, 
sparing the posterior pole (and circumventing 
enlargement of macular scars with time) (30). Thus, 
repeated prolonged anti-VEGF therapy or 
dexamethasone implant are dodged since they 
(especially the latter) carry the risk of endophthalmitis, 
retinal vascular occlusion (31), and various potential 
systemic side effects. Wessel et al. (29) proposed 
combining focal macular laser, anti-VEGF 
pharmacotherapy and retinal photocoagulation to areas 
of ischemia. Takamura et al. (32) noted that targeted 
retinal photocoagulation for nonperfused areas 
decreased the risk of recurrence of DME after intravitreal 
injection of bevacizumab. 
Our technique places laser therapy as the core treatment 
while others have used it as adjunctive to focal or anti-
VEGF or combination. Although conventional laser PRP is 
somewhat effective in decreasing angiogenesis, it causes 
side effects, such as retinal scarring at the arcade and 
decreased peripheral, color, and night vision (33). Aiming 
at the extreme periphery and applying minimal laser 
energy can significantly decrease the above 
complications. It should be noted that patients do not 
notice many scotomas following conventional PRP 
because of perceptual compensational filling-in 
generated by a mechanism of plasticity of the visual 
cortex (34). 
Several reports regarding light-energy PRP also referred 
to the technique as minimum intensity photocoagulation 
(MIP) (35, 36). Limited studies found that MIP is 
associated with fewer complications. In one study, MIP 
was associated with decrease in foveal thickness on OCT 
12 months after therapy (36).  
Retinal photocoagulation produces its therapeutic 
benefit by the following mechanisms: 
1. Destruction of the most metabolically active cells, 
decreasing the ischemic drive and secretion of 
angiogenic factors 
2. Reduction of the total retinal oxygen demand as well 
as improvement of intraretinal oxygen delivery (37, 38) 
3. Vasoconstrictive effect with the resultant decrease in 
vascular leakage (39, 40) 
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4. Facilitation of PVD formation (release of vitreomacular 
traction, increased oxygen in the vitreous cavity). 
CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSION 
Traditional angiography is likely to miss major peripheral 
nonperfusions. Identification of specific areas of the 
nonperfused retina enables targeted extrafoveal laser 
photocoagulation in the treatment of DME. In the end, 
these areas of nonperfusion advance and necessitate 
serial wide-field angiograms and repeated selective 
peripheral laser. If additional laser treatment is required, 
it can be applied in a step-wise fashion. In practical 
terms, one session of panretinal peripheral laser is more 
convenient for the patient and clinician, especially in 
centers that lack wide-angle IVFA systems. Instead of 
repetitive VEGF suppression, we offer peripheral 
(preequatorial) PRP resulting in decreased VEGF 
production, stabilization or improvement in DME, and 
long-term protection from both PDR and neovascular 
glaucoma. This procedure is applicable for all patients 
with more laser treatments applied. 
Anti-VEGF therapies, either corticosteroids or specific 
anti-VEGF agents, are given initially to act as a “jump” 
start and to remove the intraocular VEGF. As the outer-
end periphery constantly produces new VEGF, new areas 
of nonperfusion in the posterior pole, additional 
injections may be needed at a reduced frequency. This 
approach reduces the cost of treatment substantially, as 
anti-VEGF injections are more than just a time-
consuming burden for the health service. On the other 
hand, one session of laser is easily affordable, accessible, 
and attractive. The scheme currently employed for anti-
VEGF application is scheduled as two injections in the 
first year and a single injection yearly vs. 12 injections in 
the study that lead to approval of the agent (4). We 
expect that there will be a need for anti-VEGF therapy as 
the outer-end periphery is not accessible to the most of 
up-to-date wide-angle laser lenses. These outer-end 
areas are accessible to peripheral cryopexy or indirect 
laser retinopexy with scleral indentation. 
 Gardner et al (41) noted improvement in DME in poor 
vision eyes after panretinal photocoagulation (PRP).  
Their study group consisted of cases where PDR was 
managed using green laser (3-4 weekly sessions). Six 
months later, 13 of the 18 eyes demonstrated reduction 
of DME. The current technique is to be applied in 
proliferative and nonproliferative retinopathy, and the 
laser is to be administered preferentially to the outer-
end periphery, unlike the ETDRS protocol (41). There is 
also benefit from initial use of anti-VEGF in combination 
with peripheral PRP. Ferraz et al. (42) in a randomized 
study compared PRP with intravitreal ranibizumab versus 
PRP alone in DME. Visual acuity was significantly better 
at 6 months in the ranibizumab group; central macular 
thickness decreased significantly at 6 months in the 
ranibizumab group and was unchanged in the 
photocoagulation group. 
In conclusion, more than 25 years ago, the ETDRS proved 
that focal laser photocoagulation decreased the risk of 
moderate visual loss. The advent of anti-VEGF therapy 
and refinement of retinal imaging techniques have 
revolutionized our approach to DME. Ultra wide-field 
angiography provided visualization of peripheral retinal 
ischemia in DME, supporting the hypothesis that areas of 
untreated, retinal nonperfusion may be the sources of 
biochemical mediators that promote macular edema. 
Mild laser ablation to the outer-end periphery would 
theoretically decrease DME via several mechanisms 
downregulation of VEGF and other mediators, induction 
of PVD, decrease in retinal periphery leakage towards the 
fovea, and increase in the oxygen availability to the 
posterior pole. Research has begun to test this 
hypothesis in a clinical setting. 
 
DISCLOSURE 
AMM - Consultant for Bayer, Leverkusen, Germany and 
there is no interests related to the subject of this article. 
The study received no funding. 
 
REFERENCES 
1. Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. 
Neutralization of vascular endothelial growth factor slows progression 
of retinal nonperfusion in patients with diabetic macular edema. 
Ophthalmology. 2014 Sep;121(9):1783-9. PMID: 24768239. 
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary 
intravitreal bevacizumab (avastin) for diabetic macular edema. Results 
from the Pan-American Collaborative Retina Study Group at 6-month 
follow-up. Ophthalmology. 2007 Apr;114(4):743-50. PMID: 17398322. 
3. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective 
randomized controlled trial of intravitreal bevacizumab or laser therapy 
(BOLT) in the management of diabetic macular edema: 24-month data: 
report 3. Arch Ophthalmol. 2012 Aug;130(8):972-9. PMID: 22491395. 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2015; 4(4)  
 
134 DIABETIC MACULAR EDEMA 
4. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current 
treatments in diabetic macular oedema: systematic review and meta-
analysis. BMJ Open. 2013 Mar 1;3(3).  PMID:  23457327. 
5. Jyothi S, Sivaprasad S. Five-year visual outcome following laser 
photocoagulation of diabetic macular oedema. Eye (Lond). 2011 
Jul;25(7):851-8; quiz 859. PMID: 21587271. 
6. ETDRS research group. Photocoagulation for diabetic macular 
edema. Early Treatment Diabetic Retinopathy Study report number 1. 
Arch Ophthalmol. 1985 Dec;103(12):1796-806. PMID: 2866759. 
7. Early photocoagulation for diabetic retinopathy. ETDRS report 
number 9. Early Treatment Diabetic Retinopathy Study Research Group. 
Ophthalmology. 1991 May;98(5 Suppl):766-85. PMID: 2062512. 
8. Diabetic Retinopathy Clinical Research Network. Comparison of 
modified-ETDRS and mild macular grid laser photocoagulation 
strategies for diabetic macular edema. Arch Ophthalmol. 2007 
Apr;125(4):469-80. PMID: 17420366. 
9. Luttrull JK, Spink CJ. Serial optical coherence tomography of 
subthreshold diode laser micropulse photocoagulation for diabetic 
macular edema. Ophthalmic Surg Lasers Imaging. 2006 Sep-
Oct;37(5):370-7. PMID: 17017196. 
10. Dorin G. Evolution of retinal laser therapy: minimum intensity 
photocoagulation (MIP). Can the laser heal the retina without harming 
it? Semin Ophthalmol. 2004 Mar-Jun;19(1-2):62-8. PMID: 15590536. 
11. Kaines A, Oliver S, Reddy S, Schwartz SD. Ultrawide angle 
angiography for the detection and management of diabetic 
retinopathy. Int Ophthalmol Clin. 2009 Spring;49(2):53-9. PMID: 
19349786. 
12. Oliver SC, Schwartz SD. Peripheral vessel leakage (PVL): a new 
angiographic finding in diabetic retinopathy identified with ultra wide-
field fluorescein angiography. Semin Ophthalmol. 2010 Jan-Mar;25(1-
2):27-33. PMID: 20507194. 
13. Oliver SC, Schwartz SD. Peripheral vessel leakage (PVL): a new 
angiographic finding in diabetic retinopathy identified with ultra wide-
field fluorescein angiography. Semin Ophthalmol. 2010 Jan-Mar;25(1-
2):27-33. PMID: 20507194. 
14. Sim DA, Keane PA, Rajendram R, Karampelas M, Selvam S, Powner 
MB, Fruttiger M, Tufail A, Egan CA. Patterns of peripheral retinal and 
central macula ischemia in diabetic retinopathy as evaluated by ultra-
widefield fluorescein angiography. Am J Ophthalmol. 2014 
Jul;158(1):144-153.e1. PMID: 24709807. 
15. Kong M,  Lee MY, Ham D. Ultrawide-field fluorescein angiography 
for evaluation of diabetic retinopathy. Korean J Ophthalmol. 2012 
Dec;26(6):428-31.  PMID: 23204797. 
16. Soliman AZ, Silva PS, Aiello LP, Sun JK. Ultra-wide field retinal 
imaging in detection, classification, and management of diabetic 
retinopathy. Semin Ophthalmol. 2012 Sep-Nov;27(5-6):221-7. PMID: 
23163280. 
17. Koushan K, Chalam KV. Miniaturized high-resolution wide-field 
contact lens for panretinal photocoagulation. Clin Ophthalmol. 2014 
Apr 7;8:703-6. PMID: 24741290. 
18. Mainster MA, Reichel E, Harrington PG. A wide-field, high-resolution 
ophthalmoscopic contact lens. Ophthalmic Surg Lasers Imaging. 2003 
Jan-Feb;34(1):76-7. PMID: 12570012. 
19. Mainster MA, Crossman JL, Erickson PJ, Heacock GL. Retinal laser 
lenses: magnification, spot size, and field of view. Br J Ophthalmol. 
1990 Mar;74(3):177-9. PMID: 2322517. 
20. Sebag J, Buzney SM, Belyea DA, Kado M, McMeel JW, Trempe CL. 
Posterior vitreous detachment following panretinal laser 
photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1990;228(1):5-8. 
PMID: 2311946. 
21. Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H. Posterior 
vitreous detachment following intravitreal drug injection. Graefes Arch 
Clin Exp Ophthalmol. 2013 Jul;251(7):1691-5.  PMID: 23381655. 
22. Wise GN, Wangvivat Y. The exaggerated macular response to retinal 
disease. Am J Ophthalmol. 1966 May;61(5 Pt 2):1359-63. PMID: 
5938021. 
23. Otani T, Yamaguchi Y, Kishi S. Serous macular detachment 
secondary to distant retinal vascular disorders. Retina. 2004 
Oct;24(5):758-62. PMID: 15492631. 
24. Shimizu K, Kobayashi Y, Muraoka K. Midperipheral fundus 
involvement in diabetic retinopathy. Ophthalmology. 1981 
Jul;88(7):601-12. PMID: 6167923. 
25. Niki T, Muraoka K, Shimizu K. Distribution of capillary nonperfusion 
in early-stage diabetic retinopathy. Ophthalmology. 1984 
Dec;91(12):1431-9. PMID: 6084212. 
26. Freyler H. Peripheral fluorescence angiography in diabetic 
retinopathy. Klin Monbl Augenheilkd. 1985 Mar;186(3):184-6. PMID: 
3999600. 
27. Cardillo Piccolino F, Zingirian M, Mosci C. Classification of 
proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 
1987;225:245-250.  
28. Kimble JA, Brandt BM, McGwin G Jr. Clinical examination accurately 
locates capillary nonperfusion in diabetic retinopathy. Am J 
Ophthalmol. 2005 Mar;139(3):555-7.  PMID: 15767077. 
29. Wessel MM, Aaker GD, Parlitsis G, Cho M, D'Amico DJ, Kiss S. Ultra-
wide-field angiography improves the detection and classification of 
diabetic retinopathy. Retina. 2012 Apr;32(4):785-91. PMID: 22080911. 
30. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive 
enlargement of laser scars following grid laser photocoagulation for 
diffuse diabetic macular edema. Arch Ophthalmol. 1991 
Nov;109(11):1549-51. PMID: 1755735. 
31. Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz 
SG; Collaborative Anti-VEGF Ocular Vascular Complications Group. 
Insight into 144 patients with ocular vascular events during VEGF 
antagonist injections. Clin Ophthalmol. 2012;6:343-63. PMID: 
22419856. 
32. Takamura Y, Tomomatsu T, Matsumura T, et al. The effect of 
photocoagulation in ischemic areas to prevent recurrence of diabetic 
macular edema after intravitreal bevacizumab injection. Invest 
Ophthalmol Vis Sci. 2014 Jul 15;55(8):4741-6. PMID: 25028357. 
33. Fong DS, Girach A, Boney A. Visual side effects of successful scatter 
laser photocoagulation surgery for proliferative diabetic retinopathy: a 
literature review. Retina. 2007 Sep;27(7):816-24. PMID: 17891003. 
34. Dosso AA, Ustun-Yenice F, Safran AB. Scotomata from panretinal 
photocoagulation are not perceived as a result of perceptual filling-in 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2015; 4(4)  
 
135 DIABETIC MACULAR EDEMA 
generated by plasticity in the visual cortex. Diabetes Care. 2000 
Dec;23(12):1855. PMID: 11128369. 
35. Dorin G. Evolution of retinal laser therapy: minimum intensity 
photocoagulation (MIP). Can the laser heal the retina without harming 
it?  Semin Ophthalmol. 2004 Mar-Jun;19(1-2):62-8. PMID: 15590536. 
36. Soiberman U, Goldstein M, Pianka P, Loewenstein A, Goldenberg D. 
Preservation of the photoreceptor layer following subthreshold laser 
treatment for diabetic macular edema as demonstrated by SD-OCT. 
Invest Ophthalmol Vis Sci. 2014 May 8;55(5):3054-9. PMID: 24736051. 
37. Weiter JJ, Zuckerman R. The influence of the photoreceptor-RPE 
complex on the inner retina. An explanation for the beneficial effects of 
photocoagulation. Ophthalmology. 1980 Nov;87(11):1133-9. PMID: 
6972502. 
38. Budzynski E, Smith JH, Bryar P, Birol G, Linsenmeier RA. Effects of 
photocoagulation on intraretinal PO2 in cat. Invest Ophthalmol Vis Sci. 
2008 Jan;49(1):380-9. PMID: 18172116. 
39. Liu H, Zhang W, Xu Z, Caldwell RW, Caldwell RB, Brooks SE. 
Hyperoxia causes regression of vitreous neovascularization by 
downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci. 
2013 Feb 1;54(2):918-31. PMID: 23307955. 
40. Mendrinos E, Mangioris G, Papadopoulou DN, Dosso AA, Pournaras 
CJ. Retinal vessel analyzer measurements of the effect of panretinal 
photocoagulation on the retinal arteriolar diameter in diabetic 
retinopathy. Retina. 2010 Apr;30(4):555-61.  PMID: 20010452. 
41. Gardner TW, Eller AW, Friberg TR. Reduction of severe macular 
edema in eyes with poor vision after panretinal photocoagulation for 
proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 
1991;229(4):323-8. PMID: 1916318. 
42. Ferraz DA, Vasquez LM, Preti RC, Motta A, Sophie R, Bittencourt 
MG, Sepah YJ, Monteiro ML, Nguyen QD, Takahashi WY. A randomized 
controlled trial of panretinal photocoagulation with and without 
intravitreal ranibizumab in treatment-naïve eyes with non-high-risk 
proliferative diabetic retinopathy. Retina. 2015 Feb;35(2):280-7. PMID: 
25272318. 
